한빛사 논문
Elizabeth Park1, 2, Yunha Kim,4 Hyun Ryu1, 2, Neil W. Kowall1, 2, 3, Junghee Lee1, 2, 3, Hoon Ryu 1, 2, 3, 4,*
1 Department of Neurology, Boston University School of Medicine, Boston, USA
2 Boston University Alzheimer’s Disease Center, Boston, USA
3 Department of Neurology, VA Boston Healthcare System, Boston, USA
4 Laboratory for Neuronal Gene Regulation and Epigenetics, Center for Neuro-Medicine, Brain Science Institute, Korea Institute of Science and Technology, Seoul, South Korea
Elizabeth Park and Yunha Kim have equally contributed to this work.
*Correspondence
Abstract
Rubinstein-Taybi syndrome (RTS) is an incurable genetic disorder with combination of mental retardation and physical features including broad thumbs and toes, craniofacial abnormalities, and growth deficiency. While the autosomal dominant mode of transmission is limitedly known, the majority of cases are attributable to de novo mutations in RTS. The first identified gene associated with RTS is CREB-binding protein (CREBBP/CBP). Alterations of the epigenetic ‘histone code’ due to dysfunction of the CBP histone acetyltransferase activity deregulate gene transcriptions that are prominently linked to RTS pathogenesis. In this review, we discuss how CBP mutation contributes to modifications of histone and how histone deacetylase inhibitors are therapeutically applicable to epigenetic conditioning in RTS. Since most genetic mutations are irreversible and therapeutic approaches are limited, therapeutic targeting of reversible epigenetic components altered in RTS may be an ideal strategy. Expeditious further study on the role of the epigenetic mechanisms in RTS is encouraged to identify novel epigenetic markers and therapeutic targets to treat RTS.
Keywords : RTS, Histone acetylation, Histone methylation, CBP, HDAC
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기